Medical Expenditures Associated With Diabetes Among Privately Insured U.S. Youth in 2007

OBJECTIVE To estimate, among privately insured youth in the U.S., medical expenditures associated with diabetes and the difference in medical expenditures between individuals with insulin-treated diabetes mellitus (ITDM) and with non-ITDM (NITDM). RESEARCH DESIGN AND METHODS Using the 2007 MarketScan commercial claims and encounter database, we analyzed data for 49,356 youth (aged ≤19 years) who were continuously enrolled in fee-for-service health plans. Youth with diabetes (cases) were identified from inpatient, outpatient, and pharmaceutical drug claims. Each case was matched with five controls (without diabetes) by age (±2 years), sex, census region, and urban versus rural residence. We used regression models to estimate medical expenditures in total and by component (inpatient, outpatient, and medication). RESULTS The predicted mean annual total per-person medical expenditures were $9,061 for youth with diabetes and $1,468 for those without, an excess of $7,593 for those with diabetes; of which, 43% was for prescription drugs. The predicted mean annual total expenditures were $9,333 for ITDM youth and $5,683 for NITDM youth, respectively, an excess of $3,650 for those with ITDM diabetes, of which 59% was for prescription drugs. CONCLUSIONS The excess medical expenditures associated with diabetes, ITDM in particular, among youth are substantial. Our estimates of excess expenditures can be used to assess the economic burden of diabetes overall and by diabetes treatment mode. Our estimated excess expenditure for NITDM may be used for evaluating the economic efficiency of interventions aimed at preventing type 2 diabetes in U.S. youth.

[1]  D. Lairson,et al.  Predictors of direct costs of diabetes care in pediatric patients with type 1 diabetes , 2011, Pediatric diabetes.

[2]  A. Green,et al.  Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study , 2009, The Lancet.

[3]  B. Waitzfelder,et al.  Type 1 and Type 2 Diabetes in Asian and Pacific Islander U.S. Youth , 2009, Diabetes Care.

[4]  W. Manning,et al.  Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.

[5]  J. Stockman,et al.  Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study , 2011 .

[6]  Desmond E. Williams,et al.  The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study , 2006, Pediatrics.

[7]  Darios Getahun,et al.  Contribution of Hypoglycemia to Medical Care Expenditures and Short-Term Disability in Employees With Diabetes , 2005, Journal of occupational and environmental medicine.

[8]  D Y Lin,et al.  Methods for analyzing health care utilization and costs. , 1999, Annual review of public health.

[9]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[10]  M. Engelgau,et al.  Cost-of-Illness Studies in Diabetes Mellitus , 2012, PharmacoEconomics.

[11]  W. Rathmann,et al.  Direct costs of pediatric diabetes care in Germany and their predictors. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[12]  Direct Health Care Costs of Patients With Type 2 Diabetes Within a Privately Insured Employed Population, 2000 and 2005 , 2009, Journal of occupational and environmental medicine.

[13]  T. Gilmer,et al.  Predictors of health care costs in adults with diabetes. , 2005, Diabetes care.

[14]  Michael M Engelgau,et al.  Use of Services by Diabetes Patients in Managed Care Organizations: Development of a diabetes surveillance system , 1998, Diabetes Care.

[15]  Terry N Flynn,et al.  Use of the bootstrap in analysing cost data from cluster randomised trials: some simulation results , 2004, BMC health services research.

[16]  C. Neslusan,et al.  Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. , 2003, Diabetes care.

[17]  J. Carstensen,et al.  Age‐specific direct healthcare costs attributable to diabetes in a Swedish population: a register‐based analysis , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[18]  Dana Dabelea,et al.  Diabetes in Non-Hispanic White Youth , 2009, Diabetes Care.

[19]  Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046 , 2013, Diabetes Care.

[20]  J. Leahy.  Economic Costs of Diabetes in the U.S. in 2007 , 2008 .

[21]  P. Kavanagh,et al.  Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States , 2009, Pediatric Blood & Cancer.

[22]  David M. Adamson,et al.  HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases , 2008 .

[23]  Dana Dabelea,et al.  Incidence of diabetes in youth in the United States. , 2007, JAMA.